Events

NMS Group- Nerviano Medical Sciences will participate to the 2023 BIO Europe partnering event, which will be held in Munich from November 6th to 8th and online from November 14th to 15th, 2023.  

(Click the title for the complete article)

NERVIANO, IT and BOSTON, Mass, October 2, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today it will present initial data from the PARP1 inhibitor Phase 1 studies at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15 in Boston, MA.

(Click the title for the complete article)

Nerviano Medical Sciences S.r.l., a member of NMS Group S.p.A and a clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, is proud to announce its participation to the World ADC 2023 summit that will be held in San Diego (CA) from October 16th to October 19th, 2023, with two poster presentations

(Click the title for the complete article)

La EBW è una settimana di eventi e incontri in tutta Europa per raccontare le biotecnologie nei diversi settori di applicazione ad un pubblico vasto e diversificato, sottolineando il ruolo chiave che queste tecnologie hanno nel migliorare la qualità della vita di tutti noi.

(Click the title for the complete article)

Visit Accelera Team at the 57th Congress of the European Societies of Toxicology (EUROTOX 2023). Ljubljana, Slovenia, (September 10-13)
(Click the title for the complete article)

NERVIANO, 4 April 2023 – Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that data from the  Phase I/II clinical study of NMS-03592088 in Acute Myeloid Leukemia  will be reported in an oral presentation by Dr. Antonio Curti, MD, PhD,  IRCCS Azienda Ospedaliero-Universitaria di Bologna, at the upcoming AACR Annual Meeting which will be held April 14 – 19, Orange County Convention Center, Orlando, Florida.
(Click the title for the complete article)

Visit Accelera Team

at the SOT 2023 Annual Meeting in Nashville, Tennessee

March 19 – 23
Booth #1214

Visit our booth for an overview of our services
(Click the title for the complete article)

Accelera è Sponsor del 21° congresso nazionale SITOX che si svolgerà a Bologna il giorno 21 febbraio (dalle 11.00 alle 12.00), presenterà il poster “Valutazione preclinica della tossicità a carico del SNC nel soggetto pediatrico: tecniche istologiche in neonati di ratto”.

nella sessione P3 Farmaci
Numero del poster: P3/1

(Click the title for the complete article)

Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today shared data from the Company’s Phase I/II clinical study of NMS-01940153E in Hepatocellular carcinoma (HCC) in an oral presentation by Dr. Maria Reig at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics  (ENA 2022)  in Barcelona.
(Click the title for the complete article)

Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that preclinical data from the Company’s asset NMS-03602173 will be reported in a poster presentation by Dr. Paola Magnaghi at the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics  (ENA 2022)  which will be held October 26-28, 2022 at the CCIB in Barcelona.
(Click the title for the complete article)